Related Experiment Video
Updated: Jun 22, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
How to achieve renal protection in the light of ONTARGET?
Christos Chatzikyrkou1, Jan Menne, Hermann Haller
1Department of Nephrology and Hypertension, Medical School, Hannover, Germany.
Abstract:
Inhibition of the renin-angiotensin system (RAS) either with an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) has been shown to be beneficial for cardiorenal protection. The combination of both is an exciting prospect and pathophysiologically plausible. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study provides evidence that dual blockade does not further reduce cardiovascular events or worsen renal outcomes. However, in patients with existing diabetic nephropathy, a trend towards a better outcome was observed. Therefore, combination of ARBs and ACEIs could be an alternative for selected patients, but not a standard approach in the management of chronic kidney disease. The benefits of dual blockade on hard renal endpoints remain to be shown.
Insights
Dual renin-angiotensin system blockade with ACE inhibitors and ARBs offers no additional cardiorenal protection over monotherapy. However, it may benefit selected patients with diabetic nephropathy.
Area of Science:
- Cardiovascular medicine
- Nephrology
- Pharmacology
Background:
- Renin-angiotensin system (RAS) inhibition using ACE inhibitors (ACEI) or ARBs benefits cardiorenal protection.
- Combining ACEI and ARBs (dual blockade) is pathophysiologically plausible for enhanced effects.
Purpose of the Study:
- To evaluate the efficacy and safety of dual RAS blockade compared to monotherapy.
Main Methods:
- The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study.
- Compared cardiovascular events and renal outcomes in patients receiving telmisartan alone, ramipril alone, or the combination.
Main Results:
- Dual blockade did not significantly reduce cardiovascular events or worsen renal outcomes compared to monotherapy.
- A trend towards better outcomes was observed in patients with existing diabetic nephropathy.
Conclusions:
- Dual RAS blockade is not recommended as a standard approach for chronic kidney disease management.
- Combination therapy may be considered for selected patients, particularly those with diabetic nephropathy, but benefits on hard renal endpoints require further investigation.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...

